<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03991078</url>
  </required_header>
  <id_info>
    <org_study_id>IIS-COL-2018-01</org_study_id>
    <secondary_id>1812-FIVI-100-AP</secondary_id>
    <nct_id>NCT03991078</nct_id>
  </id_info>
  <brief_title>Effect of Vitamin D on the Size of Fibroids in Women With Vitamin D Deficiency</brief_title>
  <official_title>Pilot Clinical Study to Evaluate the Effect of Vitamin D on the Size of Fibroids in Women With Vitamin D Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación IVI</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Universitario La Fe</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación IVI</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitamin D supplementation in patients with uterine fibroids who present hypovitaminosis D to
      re-establish their normal serum values could stabilize the size of the uterine fibroids and
      thus prevent their growth or reduce their size thanks to the anti-proliferative action of
      Vitamin D on the myoma cells.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 9, 2019</start_date>
  <completion_date type="Anticipated">June 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 25, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>volume of the uterine fibroids</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Size of the Uterine Fibroids</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with uterine fidroids and hypovitaminosis D
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with at least one fibroid &gt; 3 cm

          -  With hypovitaminosis D (25(OH)D &lt; 30 ng/ml)

          -  BMI &lt; 30

          -  No hormonal treatment in the 3 months prior to the ultrasound study

        Exclusion Criteria:

          -  Black race

          -  Symptomatic fibroids subsidiary to hormonal or surgical treatment

          -  Desire of gestation in the next 6 months

          -  Presence of degenerating adenomyosis or fibroids

          -  Treatment with sexual hormones: mifepristone, aGnRH or any other medication that may
             interfere with fibroids.

          -  History of neoplasia of gynecological origin and/or existence of uterine
             malformations.

          -  Hypercalcemia or abnormal liver or kidney function is present
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Pellicer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundación IVI</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hortensia Ferrero, phD</last_name>
    <phone>+34963903305</phone>
    <email>Hortensia.Ferrero@ivirma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fundacion IVI</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hortensia Ferrero, PhD</last_name>
      <phone>+34963903305</phone>
      <email>Hortensia.Ferrero@ivirma.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 17, 2019</study_first_submitted>
  <study_first_submitted_qc>June 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2019</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

